The expanding companion animal population, pet humanization, animal disease incidence, and significant company initiatives are the main drivers of market growth in the country. Boehringer Ingelheim, for example, got clearance from China's Ministry of Agriculture and Rural Affairs in May 2021 for GastroGard, a horse-specific medication. Boehringer Ingelheim became the first global animal health company to have an equestrian business in China as a result of this. The impact of the COVID-19 epidemic on the market was mixed. For certain market actors, the negative consequences of mobility limitations and logistical challenges resulted in poor demand and sales.